Laurus Labs reported results for fourth quarter (Q4) and year ended March 31, 2023.
Laurus Labs has reported 53.77% fall in its net profit at Rs 102.28 crore for the quarter under review as compared to Rs 221.22 crore for the same quarter in the previous year. Total income of the company decreased by 6.86% at Rs 1,285.28 crore for Q4FY23 as compared to Rs 1,379.95 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 53.76% fall in its net profit at Rs 107.24 crore for fourth quarter ended March 31, 2023 as compared to Rs 231.90 crore for the same quarter in the previous year. Total income of the company decreased by 3.05% at Rs 1,382.61 crore for Q4FY23 as compared to Rs 1,426.12 crore for the corresponding quarter previous year.
For the year ended March 31, 2023, the company has reported 1.37% rise in its net profit at Rs 760.38 crore as compared to Rs 750.09 crore for the previous year. Total income of the company increased by 22.43% at Rs 5,789.40 crore for year under review as compared to Rs 4,728.59 crore for year ended March 31, 2022.
For the year ended March 31, 2023, on the consolidated basis, the company has reported 4.30% fall in its net profit at Rs 796.64 crore as compared to Rs 832.43 crore for the previous year. However, total income of the company increased by 22.13% at Rs 6,046.55 crore for year under review as compared to Rs 4,950.87 crore for year ended March 31, 2022.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1861.70 |
Dr. Reddys Lab | 1389.35 |
Cipla | 1506.15 |
Lupin | 2228.00 |
Zydus Lifesciences | 972.70 |
View more.. |